首頁 > 市場調查報告書 > 製藥

呼吸器

市場調查報告書

商品編碼

1733627

2026 年至 2032 年慢性阻塞性肺病市場（按類型、治療類型、最終用戶和地區分類）

Chronic Obstructive Pulmonary Disease Market By Type (Chronic Bronchitis, Emphysema), Treatment Type (Drugs, Surgery, Oxygen Therapy), End-User (Hospitals, Clinics, Homecare Settings), & Region for 2026-2032

出版日期: 2025年04月29日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

慢性阻塞性肺病市場評估－2026-2032

在全球範圍內，慢性阻塞性肺病的盛行率不斷上升，推動了慢性阻塞性肺病的蔓延。由於青少年菸草消費量的增加以及大眾對學名藥使用的認知不斷提高，預計到 2024 年市場規模將超過 211.7 億美元，到 2032 年將達到約 353 億美元的估值。

此外，新興國家醫療支出的增加也刺激了慢性阻塞性肺病的治療。政府和大公司不斷增加的研發投入使得市場在 2026 年至 2032 年期間的複合年成長率達到 7.28%。

慢性阻塞性肺病市場定義/概述

慢性阻塞性肺病(COPD)，也稱為肺氣腫或慢性支氣管炎，是一種導致氣流受限和呼吸問題的肺部疾病。症狀包括咳嗽、呼吸困難、喘息和疲勞。常見原因包括吸煙和空氣污染，患有 COPD 的人患其他健康問題的風險更高。慢性支氣管炎會導致支氣管發炎，進而導致支氣管腫脹和黏液積聚，使支氣管開口變窄，使空氣更難進出肺部。肺氣腫是肺部底部氣囊（肺泡）被破壞的疾病，它就像一棵倒置的樹，氣管是樹幹，支氣管是樹枝，肺泡是樹葉。

慢性阻塞性肺病(COPD) 的治療重點是緩解症狀、改善生活品質和減緩病情進展。治療的主要內容包括使用支氣管擴張劑（放鬆呼吸道肌肉並改善氣流）、吸入性皮質類固醇（抑制發炎）以及組合吸入藥物（增強療效）。包括運動訓練、營養建議和教育的肺部復健計畫對於增強患者能力和改善功能至關重要。在嚴重的情況下，可能需要補充氧氣治療。此外，戒菸對於阻止疾病進展至關重要，而接種疫苗和定期監測可以幫助防止病情惡化並有效控制合併症。

COPD 治療的未來可能集中在個人化醫療、先進的藥物傳輸系統和創新治療方法。主要趨勢包括針對特定發炎途徑的生技藥品、用於肺組織修復的基因和再生療法、遠端醫療和遠端監控等數位健康技術以及新的吸入器技術和藥物製劑。這些進步旨在改善 COPD 患者的治療效果和生活品質，並加強患者管理和治療計劃的依從性。

提高對慢性阻塞性肺病(COPD) 的認知將如何增加慢性阻塞性肺病的採用？

人們對慢性阻塞性肺病(COPD) 的認知日益加深，全球範圍內的診斷和認知度也相應提高。提高醫療專業人員和公眾的認知對於早期發現 COPD 至關重要，這樣才能及時介入並制定更好的管理策略。因此，人們越來越需要改進診斷工具、更有效的治療方法以及更好地了解和控制 COPD 的研究。這種不斷變化的情況凸顯了教育和積極主動的醫療保健舉措對於減少 COPD 對個人和醫療保健系統的影響的重要性，從而推動了市場成長。

全球慢性阻塞性肺病 (COPD) 盛行率的不斷上升是一項重大的公共衛生挑戰，部分原因是吸煙，而吸煙仍然是 COPD 的主要危險因素。全球成年人吸菸率的上升導致慢性阻塞性肺病的負擔日益加重，凸顯了全面戒菸計畫和加強菸草控制的迫切需求。此外，職業暴露於污染物和室內空氣污染進一步加劇了 COPD 的風險。透過監管政策和職場干預來解決這些環境因素對於限制 COPD 的發生和發展至關重要，從而改善受影響個人的生活品質並減輕醫療資源的負擔。

肺量計、電腦斷層掃描和生物標記檢測等診斷技術的進步顯著改善了慢性阻塞性肺病(COPD) 的管理。這些技術可以實現更早的發現、個人化的治療計劃和更好的症狀控制。此外，支氣管擴張劑、皮質類固醇和生技藥品等治療方案也改善了 COPD 患者的生活品質。例如，2021年2月，賽諾菲和再生元製藥啟動了一項III期臨床試驗，以評估itepekimab在抑制戒菸者COPD急性加重方面的療效和安全性，該試驗計劃於2024年7月完成。

用於治療慢性阻塞性肺病（COPD）的藥物副作用的增加是否會限制其採用？

用於治療慢性阻塞性肺病(COPD) 的藥物的副作用日益增加，嚴重阻礙了市場的成長。據美國國家生物技術資訊中心稱，吸入類固醇等藥物會導致口腔感染疾病、瘀傷和聲音沙啞，妨礙患者的依從性並限制市場擴張。此外，使用這些藥物的 COPD 患者更容易感染流感、感冒和肺炎等呼吸道感染疾病，這進一步使治療複雜化並增加了醫療成本。

此外，COPD 的複雜性和患者對治療反應的多變性使得藥物開發尤為具有挑戰性。第二階段 TERRANOVA 和 GALATHEA 試驗等臨床試驗往往難以證明其療效和安全性，進一步阻礙了 COPD 市場的進步。藥物研發的這種不確定性阻礙了投資並減緩了新治療方法的推出。

開發新藥面臨許多挑戰，包括臨床試驗的高失敗率。例如，2019年5月，氣喘治療藥物貝那利珠單抗未能降低中度至極重度 COPD 患者的 COPD 年發作率。這些挫折凸顯了發現有效治療方法的難度，限制了市場的成長前景。

與 COPD 相關的併發症，如憂鬱症、心臟病、肺動脈高壓和肺癌也對有效管理和市場成長構成了挑戰。這些併發症的嚴重性需要採取綜合治療方法，但這通常成本高昂且耗費資源，從而限制了市場的成長。

AstraZeneca
Boehringer Ingelheim
GlaxoSmithKline（GSK）
Novartis
Merck & Co.
Pfizer
Teva Pharmaceuticals
Sanofi
Mylan
Chiesi Farmaceutici
Sunovion Pharmaceuticals
Orion Corporation
Cipla
Reddy's Laboratories
Vectura Group
Circassia Pharmaceuticals
Theravance Biopharma
Verona Pharma
Glenmark Pharmaceuticals
Pulmatrix

第11章市場展望與機會

新興技術
未來市場趨勢
投資機會

第12章附錄

簡稱列表
來源和參考文獻

簡介目錄

Product Code: 30532

Chronic Obstructive Pulmonary Disease Market Valuation - 2026-2032

Rising incidence of COPD among populations across the globe is propelling the adoption of chronic obstructive pulmonary disease. The increasing tobacco consumption among young people & rising public awareness of the usage of generic drugs is driving the market size surpass USD 21.17 Billion valued in 2024 to reach a valuation of around USD 35.3 Billion by 2032.

In addition to this, increasing expenditure on healthcare is giving services in emerging countries is spurring up the adoption of chronic obstructive pulmonary disease. Growing R&D investment by the government and large players is enabling the market grow at a CAGR of 7.28% from 2026 to 2032.

Chronic Obstructive Pulmonary Disease Market: Definition/ Overview

Chronic obstructive pulmonary disease (COPD), also known as emphysema or chronic bronchitis, is a lung disease causing restricted airflow and breathing issues. Symptoms include cough, difficulty breathing, wheezing, and tiredness. Common causes include smoking and air pollution, and those with COPD are at higher risk of other health issues. Chronic bronchitis causes inflammation of the bronchial tubes, causing swelling and the buildup of mucus, which narrows the tube's opening, making it difficult for air to enter and exit the lungs. Emphysema is the breakdown of air sacs (alveoli) at the bottom of the lung, similar to an upside-down tree with the windpipe as the trunk, bronchi as branches, and air sacs as leaves.

Chronic Obstructive Pulmonary Disease (COPD) treatment focuses on alleviating symptoms, improving quality of life, and slowing disease progression. Key components include bronchodilators to relax airway muscles and improve airflow, inhaled corticosteroids to reduce inflammation, and combination inhalers for enhanced efficacy. Pulmonary rehabilitation programs, encompassing exercise training, nutrition advice, and education, are crucial for patient empowerment and functional improvement. Supplemental oxygen therapy may be necessary for severe cases. Additionally, smoking cessation is vital to halt disease progression, while vaccinations and regular monitoring help prevent exacerbations and manage comorbidities effectively.

The future of COPD treatment will focus on personalized medicine, advanced drug delivery systems, and innovative therapies. Key trends include biologics targeting specific inflammatory pathways, gene therapy and regenerative medicine for lung tissue repair, digital health technologies like telemedicine and remote monitoring, and novel inhaler technologies and drug formulations. These advancements aim to improve outcomes and quality of life for COPD patients, enhancing patient management and adherence to treatment plans.

How will Rising Awareness of Chronic Obstructive Pulmonary Disease (COPD) Increase Adoption of Chronic Obstructive Pulmonary Disease?

Rising awareness of chronic obstructive pulmonary disease (COPD) continue to advance, there is a corresponding increase in the diagnosis and recognition of the condition globally. This heightened awareness among healthcare professionals and the public is crucial in identifying COPD at earlier stages, allowing for timely interventions and better management strategies. Consequently, there is a growing demand for improved diagnostic tools, more effective treatments, and increased research efforts aimed at understanding and combating COPD. This evolving landscape underscores the importance of education and proactive healthcare initiatives to mitigate the impact of COPD on individuals and healthcare systems, this is bolstering the growth of the market.

The rise in COPD cases globally presents a significant public health challenge, driven in part by factors such as tobacco smoking, which remains a leading risk factor for the disease. The increasing prevalence of adult smoking worldwide has contributed to a higher burden of COPD, highlighting the urgent need for comprehensive smoking cessation programs and stricter tobacco control measures. Additionally, occupational exposures to pollutants and indoor air pollution further exacerbate the risk of developing COPD. Addressing these environmental factors through regulatory policies and workplace interventions is crucial in reducing the incidence and progression of COPD, thereby improving the quality of life for affected individuals and lessening the strain on healthcare resources.

Advancements in diagnostic technologies like spirometry, CT scans, and biomarker testing have significantly improved the management of Chronic Obstructive Pulmonary Disease (COPD). These technologies enable early identification, personalized treatment plans, and improved symptom control. Additionally, therapeutic options like bronchodilators, corticosteroids, and biologic medicines have enhanced the quality of life for COPD patients. For instance, in February 2021, Sanofi and Regeneron Pharmaceuticals are conducting a Phase III clinical trial to evaluate the effectiveness and safety of itepekimab in reducing acute COPD exacerbations in former smokers, with the trial set to conclude in July 2024.

Will Rising Side Effects of Drugs Used in Treating Chronic Obstructive Pulmonary Disease (COPD) Restrain Its Application?

The rising side effects of drugs used in treating Chronic Obstructive Pulmonary Disease (COPD) significantly hinder market growth. According to the National Center for Biotechnology Information, medications such as inhaled steroids can cause oral infections, bruising, and hoarseness, which deter patient compliance and limit market expansion. Additionally, COPD patients on these medications are prone to respiratory infections like flu, colds, and pneumonia, further complicating their treatment and increasing healthcare costs.

Moreover, the complexity of COPD and the variability in patient response to treatments make drug development particularly challenging. Clinical trials, such as the Phase II TERRANOVA and GALATHEA studies, often struggle to demonstrate efficacy and safety, further impeding progress in the COPD market. This uncertainty in drug development discourages investment and slows the introduction of new therapies.

The development of new drugs for COPD is fraught with challenges, including high failure rates in clinical trials. For instance, in May 2019, benralizumab, an asthma drug, failed to reduce annual COPD exacerbation rates in patients with moderate to very severe COPD. Such setbacks highlight the difficulties in discovering effective treatments, limiting market growth prospects.

Complications associated with COPD, including depression, heart problems, high blood pressure in lung arteries, and lung cancer, also pose challenges to effective management and market growth. The severity of these complications necessitates comprehensive treatment approaches, which are often costly and resource-intensive, restraining market growth.

Category-Wise Acumens

Which Factors Contribute to the Dominance of Drugs Segment in Chronic Obstructive Pulmonary Disease Market?

The drugs segment dominates the chronic obstructive pulmonary disease (COPD) market, primarily due to the widespread use of bronchodilators. Bronchodilators, both short-acting and long-acting, hold a largest market share. They are crucial for managing COPD symptoms by relaxing airways and providing rapid relief from bronchospasms and exacerbations. The inhaled delivery method enhances patient compliance, making them a preferred choice for both patients and healthcare providers. As COPD progresses and lung function declines, bronchodilators become even more significant in managing symptoms and preventing exacerbations.

Corticosteroids are essential COPD drugs that reduce airway inflammation and mucus production. They are often used in combination with bronchodilators, particularly in severe COPD patients or those with frequent exacerbations. They help alleviate symptoms and improve lung function over time, but long-term use may have potential side effects, requiring careful healthcare management.

Phosphodiesterase type 4 (PDE4) inhibitors represent a newer addition to COPD treatment options. These medications work by reducing inflammation and relaxing the airways, similar to corticosteroids but through a different mechanism. PDE4 inhibitors are typically prescribed for patients with severe COPD and a history of exacerbations despite bronchodilator and corticosteroid therapy. Their role in managing COPD involves improving lung function and reducing exacerbation frequency, contributing to overall disease control and patient well-being.

The COPD market comprises various drug classes, including bronchodilators for immediate symptom relief, corticosteroids for inflammation management, and PDE4 inhibitors for symptom relief, each playing a crucial role in managing COPD symptoms and enhancing patient outcomes.

Which Factors Enhance the Use of Chronic Obstructive Pulmonary Disease in Hospitals?

Hospitals dominate the chronic obstructive pulmonary disease (COPD) market, with specialized departments like pulmonology and respiratory therapy, and advanced diagnostic capabilities like pulmonary function tests and imaging, ensuring accurate diagnosis and disease monitoring.

Hospitals offer a multidisciplinary approach to COPD management, involving pulmonologists, respiratory therapists, nurses, and rehabilitation specialists. They provide comprehensive care, addressing both medical and supportive needs. They offer a range of COPD treatments, including bronchodilators, corticosteroids, oxygen therapy, and surgical interventions. Hospitals also participate in clinical trials for innovative therapies.

Hospitals provide 24/7 emergency services, crucial for COPD patients experiencing sudden exacerbations or respiratory distress. This accessibility ensures prompt medical intervention and reduces morbidity and mortality associated with severe COPD complications.

Country/Region-wise Acumens

Will Rising Prevalence of COPD in North America Mature Chronic Obstructive Pulmonary Disease Market?

North America stands out as a dominant force in the global chronic obstructive pulmonary disease (COPD) market for several compelling reasons. The region boasts a high prevalence of COPD, attributed partly to historical smoking rates and environmental factors. This prevalence drives substantial demand for COPD treatments and healthcare services, making it a significant contributor to the market's size and growth.

North America benefits from advanced healthcare infrastructure and robust pharmaceutical industry capabilities. This infrastructure supports comprehensive diagnostic capabilities, including advanced imaging and pulmonary function tests, crucial for accurate COPD diagnosis and monitoring. Moreover, the region's strong research and development ecosystem fosters continuous innovation in COPD therapies, ensuring patients have access to cutting-edge treatments and medications.

Also, efforts to raise public awareness about public health and implement smoking cessation programs in countries such as the United States and Canada are aimed at reducing risk factors for COPD and improving early detection. These initiatives contribute to improved disease management and outcomes, further solidifying North America's position as a leader in the global COPD market.

Furthermore, healthcare policies and reimbursement frameworks in North America facilitate access to COPD treatments, including bronchodilators, corticosteroids, and biologics. This accessibility ensures that COPD patients receive timely and appropriate care, enhancing treatment adherence and overall health outcomes.

Will Increasing Air Pollution in Asia Pacific Drive the Growth of Chronic Obstructive Pulmonary Disease Market?

The Asia-Pacific region is expected to witness significant growth in the drugs segment of the chronic obstructive pulmonary disease (COPD) market during the forecast period due to the rising prevalence of COPD. Increasing air pollution and high smoking rates in countries like China and India contribute to a growing patient population, driving demand for effective treatments.

A rising prevalence of respiratory distress conditions is a major driver in the region. According to the World Health Organization (WHO), over 90% of COPD-related deaths occur in low and middle-income countries, highlighting the critical need for effective treatments in Asia-Pacific.

Moreover, the presence of a large aging population in the region, which is more susceptible to COPD, is fueling the demand for maintenance and rescue medications. This demographic trend is a key driver of market growth in the drugs segment.

Pharmaceutical companies are increasingly focusing on the Asia-Pacific market due to its high growth potential. Investments in local manufacturing and distribution networks, along with strategic partnerships, are expanding the availability and affordability of COPD drugs, thereby supporting market expansion in the region.

Competitive Landscape

The competitive landscape of the chronic obstructive pulmonary disease (COPD) market is characterized by intense competition and rapid innovation. Companies are focusing on developing advanced drug formulations and delivery systems to improve patient outcomes and adherence. Strategic collaborations, mergers, and acquisitions are common as firms aim to expand their market presence and leverage synergistic capabilities. Additionally, substantial investments in research and development, along with an emphasis on personalized medicine and biologics, are driving the evolution of treatment options, making the market highly dynamic and competitive. Some of the prominent players operating in the chronic obstructive pulmonary disease market include:

AstraZeneca

Boehringer Ingelheim

GlaxoSmithKline (GSK)

Novartis

Merck & Co.

Pfizer

Teva Pharmaceuticals

Sanofi

Mylan

Chiesi Farmaceutici

Sunovion Pharmaceuticals

Orion Corporation

Cipla

Reddy's Laboratories

Vectura Group

Circassia Pharmaceuticals

Theravance Biopharma

Verona Pharma

Glenmark Pharmaceuticals

Pulmatrix

Latest Developments

In January 2022, A phase 4 study comparing Yupelri (revefenacin) and Spiriva (tiotropium) in improving lung health in adults with severe chronic obstructive pulmonary disease (COPD) is underway. The study assesses the safety of these two approved daily COPD maintenance treatments. Yupelri, a bronchodilator developed by Theravance Biopharma and Mylan, relaxes and widens lung airways, making breathing easier. It is available as an inhalable solution via a nebulizer.

In November 2021, AstraZeneca sold the rights to commercialize Tudorza (Eklira) and Duaklir to Swiss pharmaceutical business Covis Pharma Group for US$ 270 million. The products are intended for the treatment of chronic obstructive pulmonary disease (COPD).